Subject(s)
Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antineoplastic Agents/administration & dosage , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/nursing , Clinical Trials, Phase III as Topic , Humans , Infusions, Intravenous , Injections, Subcutaneous , Lymphoma, Follicular/drug therapy , Lymphoma, Follicular/nursing , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/nursing , Rituximab , Treatment OutcomeABSTRACT
OBJECTIVE: To explore the role and outcomes using hematopoietic cell transplantation (HCT) as a treatment option with aggressive, follicular, mantle, T-cell, and HIV related non-Hodgkin's lymphoma (NHL). DATA SOURCES: Research and review articles and textbooks. CONCLUSION: High-dose chemotherapy and/or radiation therapy followed by HCT has been used to overcome resistance to standard-dose therapy and has been explored over the past 40 years and has shown long-term survival of approximately 10% to 50% in patients with relapsed or refractory lymphoma. IMPLICATIONS FOR NURSING PRACTICE: Nursing plays a significant role in the assessment and management of patients throughout the course of HCT.
Subject(s)
Hematopoietic Stem Cell Transplantation , Lymphoma, Non-Hodgkin/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/nursing , Humans , Lymphoma, AIDS-Related/nursing , Lymphoma, AIDS-Related/therapy , Lymphoma, Follicular/nursing , Lymphoma, Follicular/therapy , Lymphoma, Mantle-Cell/nursing , Lymphoma, Mantle-Cell/therapy , Lymphoma, Non-Hodgkin/nursing , Lymphoma, T-Cell/nursing , Lymphoma, T-Cell/therapy , Transplantation Conditioning/adverse effects , Transplantation Conditioning/nursingSubject(s)
Antibodies, Monoclonal/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Follicular/nursing , Lymphoma, Non-Hodgkin/nursing , Antibodies, Monoclonal, Murine-Derived , Clinical Trials as Topic , Clinical Trials, Phase III as Topic/nursing , Disease Progression , Disease-Free Survival , Humans , Lymphoma, Follicular/drug therapy , Lymphoma, Follicular/mortality , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/mortality , Rituximab , Treatment OutcomeABSTRACT
Follicular non-Hodgkin lymphoma (NHL) is an indolent, or slow-growing, malignant disease of the lymphoid tissue, which usually responds to initial therapy. However, the disease is characterized by multiple relapses and remissions, eventually causing death. Several effective therapies are available, but improvement of overall survival in patients with follicular NHL has not been demonstrated. Stimulation of the immune system to recognize malignant lymphoma cells as foreign has been demonstrated as a viable treatment option for patients with follicular NHL. Patient-specific vaccine therapy is a new form of active immunotherapy being studied for NHL. Clinical trials have shown a benefit for patients receiving this type of therapy. This article will provide a foundation for nurses caring for patients receiving patient-specific vaccine therapy.